Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rolipram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 19/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 12/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 11/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 11/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | VEGFA | P15692 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| S-Rolipram SCHEMBL5321568 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL29598924 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL27930 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| S-Rolipram SCHEMBL29475409 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| (-)-Rolipram SCHEMBL576805 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL3719855 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3544304 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL28973411 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Rolipram SCHEMBL15208132 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3554826 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102437-A1 | METHODS OF TREATING FRAGILE X SYNDROME USING PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| US-20250084236-A1 | AN ADDITIVE MIXTURE FOR STABILIZATION OF ORGANIC MATERIAL | BASF SCHWEIZ AG (CH) | 2025-03-13 | — | — | US | disclosed |
| US-20240292641-A1 | SEMICONDUCTOR ELEMENT AND SEMICONDUCTOR DEVICE | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4373886-A1 | AN ADDITIVE MIXTURE FOR STABILIZATION OF ORGANIC MATERIAL | BASF SE (DE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117677658-A | Additive mixture for stabilizing organic materials | 巴斯夫欧洲公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4126139-A1 | MULTI-CARRIER MEDICAMENT DISPENSERS | Lupin Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| WO-2023001717-A1 | AN ADDITIVE MIXTURE FOR STABILIZATION OF ORGANIC MATERIAL | BASF SE (DE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022207948-A1 | SYNTHESIS OF CHA/AEI INTERGROWTH, SYNTHESIS METHOD AND USE THEREOF IN CATALYTIC APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| EP-1907037-B2 | MEDICAMENT DISPENSER | GLAXO GROUP LTD (GB) | 2022-09-07 | — | — | EP | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| WO-2022020506-A1 | DOSE COUNTER ASSEMBLIES FOR MEDICAMENT DISPENSERS | Lupin Inc. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 12/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | PDE4A 3181/4885PDE4B 3135/4885PDE4C 2436/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | PDE4A 4859/4885PDE4B 4857/4885PDE4C 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.